Skip to Main Content

Paper Details

Microfluidic immuno-serology assay revealed a limited diversity of protection against COVID-19 in patients with altered immunity.
bioRxiv
1
2022
B cell, B cells, BCR, COVID, COVID infection, COVID-19, SARS, SARS-CoV-2, altered immunity, anti-RBD antibody, anti-spike, anti-spike IgG, autoimmune disease, autoimmune disorders, hematologic malignancies, patients
Author NameAffiliation
Dongjoo KimYale University
Giulia BianconYale School of Medicine
Zhiliang BaiYale University
Jennifer VanOudenhoveYale School of Medicine
Yuxin LiuYale School of Medicine
Shalin KothariYale School of Medicine
Lohith GowdaYale School of Medicine
Jennifer M KwanYale School of Medicine
Nicholas Carlos Buitrago-PocasangreYale University
Nikhil LeleYale University
Hiromitsu AsashimaYale University
Michael K Racke
JoDell E Wilson
Tara S Givens
Mary M TomaykoYale University
Mary M TomaykoYale School of Medicine
Wade Schulz (CM4AI)Yale School of Medicine
Erin E LongbrakeYale University
David A HaflerYale University
David A HaflerYale University
David A HaflerYale University
David A HaflerYale University
Stephanie HaleneYale School of Medicine
Stephanie HaleneYale School of Medicine
Stephanie HaleneYale Center for RNA Science and Medicine, Yale School of Medicine
Stephanie HaleneYale Cancer Center, Yale School of Medicine
Stephanie HaleneYale School of Medicine
Rong FanYale University
Rong FanYale School of Medicine
Rong FanYale Cancer Center, Yale School of Medicine
Rong FanYale School of Medicine
Rong FanYale School of Medicine
  • 1 - 32

Datasets

Release 1.2